BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32030746)

  • 1. Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohort.
    Dong L; Jin X; Wang W; Ye Q; Li W; Shi S; Guo L; Ying J; Zou S
    Int J Cancer; 2020 Jun; 146(11):3077-3086. PubMed ID: 32030746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.
    Jiang W; Cai MY; Li SY; Bei JX; Wang F; Hampel H; Ling YH; Frayling IM; Sinicrope FA; Rodriguez-Bigas MA; Dignam JJ; Kerr DJ; Rosell R; Mao M; Li JB; Guo YM; Wu XY; Kong LH; Tang JH; Wu XD; Li CF; Chen JR; Ou QJ; Ye MZ; Guo FM; Han P; Wang QW; Wan DS; Li L; Xu RH; Pan ZZ; Ding PR;
    Int J Cancer; 2019 May; 144(9):2161-2168. PubMed ID: 30521064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
    Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
    Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population.
    West NP; Gallop N; Kaye D; Glover A; Young C; Hutchins GGA; Brockmoeller SF; Westwood AC; Rossington H; Quirke P;
    Histopathology; 2021 Nov; 79(5):690-699. PubMed ID: 33872400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
    Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer.
    Xiao B; Luo J; Xie E; Kong L; Tang J; Liu D; Mao L; Sui Q; Li W; Hong Z; Pan Z; Jiang W; Ding PR
    Eur J Hum Genet; 2020 Nov; 28(11):1555-1562. PubMed ID: 32661327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients: a 10-year experience in a single Italian Cancer Center.
    Puccini A; Nardin S; Trevisan L; Lastraioli S; Gismondi V; Ricciotti I; Damiani A; Bregni G; Murialdo R; Pastorino A; Martelli V; Gandini A; Mastracci L; Varesco L; Dono M; Battistuzzi L; Grillo F; Sciallero S
    Eur J Cancer Prev; 2024 Jul; 33(4):355-362. PubMed ID: 38190337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
    Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
    Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.
    Vos JR; Fakkert IE; Spruijt L; Willems RW; Langenveld S; Mensenkamp AR; Leter EM; Nagtegaal ID; Ligtenberg MJL; Hoogerbrugge N;
    Int J Cancer; 2020 Oct; 147(8):2150-2158. PubMed ID: 32510614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.
    Haraldsdottir S; Hampel H; Wu C; Weng DY; Shields PG; Frankel WL; Pan X; de la Chapelle A; Goldberg RM; Bekaii-Saab T
    Genet Med; 2016 Sep; 18(9):863-8. PubMed ID: 26866578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based screening for Lynch syndrome in Western Australia.
    Schofield L; Grieu F; Amanuel B; Carrello A; Spagnolo D; Kiraly C; Pachter N; Goldblatt J; Platell C; Levitt M; Stewart C; Salama P; Ee H; Raftopoulous S; Katris P; Threlfall T; Edkins E; Wallace M; Iacopetta B
    Int J Cancer; 2014 Sep; 135(5):1085-91. PubMed ID: 24474394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome.
    Adar T; Rodgers LH; Shannon KM; Yoshida M; Ma T; Mattia A; Lauwers GY; Iafrate AJ; Chung DC
    Mod Pathol; 2017 Mar; 30(3):440-447. PubMed ID: 28059100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
    Chen YE; Kao SS; Chung RH
    PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.
    Schofield L; Grieu F; Goldblatt J; Amanuel B; Iacopetta B
    Fam Cancer; 2012 Mar; 11(1):1-6. PubMed ID: 22120844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of people with Lynch syndrome from those presenting with colorectal cancer in England: baseline analysis of the diagnostic pathway.
    McRonald FE; Pethick J; Santaniello F; Shand B; Tyson A; Tulloch O; Goel S; Lüchtenborg M; Borthwick GM; Turnbull C; Shaw AC; Monahan KJ; Frayling IM; Hardy S; Burn J
    Eur J Hum Genet; 2024 May; 32(5):529-538. PubMed ID: 38355963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population.
    Kumamoto K; Ishida H; Suzuki O; Tajima Y; Chika N; Kuwabara K; Ishibashi K; Saito K; Nagata K; Eguchi H; Tamaru J; Iwama T
    Surg Today; 2016 Jun; 46(6):713-20. PubMed ID: 26249337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
    Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
    Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.